Law Offices of Howard G. Smith Investigates Alleged Securities Fraud by Amicus Therapeutics, Inc.

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Amicus Therapeutics, Inc. ("Amicus" or the "Company") (Nasdaq: FOLD) concerning the Company’s and its officers’ possible violations of federal securities laws in connection with the Company’s recently announced delay in submitting a New Drug Application (“NDA”) to the Food and Drug Administration (“FDA”).

On October 2, 2015, the Company disclosed that the FDA had “requested further integration of existing clinical data across studies” in connection with Amicus’s migalastat monotherapy treatment for Fabry disease, and that, “Amicus does not anticipate being in a position to submit the NDA for migalastat monotherapy in the United States by the end of this year.” On this news, the Company’s stock fell $7.36, or over 53%, to close at $6.39 on October 2, 2015, thereby injuring Amicus investors.

If you purchased Amicus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by e-mail to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151009005138/en/